Results of the First Italian External Quality Assurance Scheme for Somatic EGFR
Results of the First Italian External Quality Assurance Scheme for Somatic EGFR
Marchetti, Antonio
2013-06-01 00:00:00
ORIGINAL ARTICLE Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non–Small-Cell Lung Cancer Nicola Normanno, MD,*† Carmine Pinto, MD,‡ GianLuigi Taddei, MD,§ Marcello Gambacorta, MD,‖ Francesca Castiglione, MD,§ Massimo Barberis, MD,¶ Claudio Clemente, MD,# and Antonio Marchetti, MD** laboratories passed the second round. Overall, 41of 47 centers (87%) Introduction: The Italian Association of Medical Oncology (AIOM) passed the EQA. and the Italian Society of Pathology and Cytology organized an Conclusion: The results of the EQA for EGFR testing in non–small- external quality assessment (EQA) scheme for EGFR mutation test- cell lung cancer suggest that good quality EGFR mutational analysis ing in non–small-cell lung cancer. is performed in Italian laboratories, although differences between Methods: Ten specimens, including three small biopsies with known testing methods were observed, especially for small biopsies. epidermal growth factor receptor (EGFR) mutation status, were vali- dated in three referral laboratories and provided to 47 participating Key Words: Non–small-cell lung carcinoma, EGFR mutations, centers. The participants were requested to perform mutational anal- Quality assessment. ysis, using their usual method, and to submit results within a 4-week time frame. According to a predefined scoring system, two points (J Thorac Oncol. 2013;8: 773-778) were assigned to correct genotype and zero points to false-negative or false-positive results. The
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngJournal of Thoracic OncologyWolters Kluwer Healthhttp://www.deepdyve.com/lp/wolters-kluwer-health/results-of-the-first-italian-external-quality-assurance-scheme-for-InKvyY9umK
Results of the First Italian External Quality Assurance Scheme for Somatic EGFR
ORIGINAL ARTICLE Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non–Small-Cell Lung Cancer Nicola Normanno, MD,*† Carmine Pinto, MD,‡ GianLuigi Taddei, MD,§ Marcello Gambacorta, MD,‖ Francesca Castiglione, MD,§ Massimo Barberis, MD,¶ Claudio Clemente, MD,# and Antonio Marchetti, MD** laboratories passed the second round. Overall, 41of 47 centers (87%) Introduction: The Italian Association of Medical Oncology (AIOM) passed the EQA. and the Italian Society of Pathology and Cytology organized an Conclusion: The results of the EQA for EGFR testing in non–small- external quality assessment (EQA) scheme for EGFR mutation test- cell lung cancer suggest that good quality EGFR mutational analysis ing in non–small-cell lung cancer. is performed in Italian laboratories, although differences between Methods: Ten specimens, including three small biopsies with known testing methods were observed, especially for small biopsies. epidermal growth factor receptor (EGFR) mutation status, were vali- dated in three referral laboratories and provided to 47 participating Key Words: Non–small-cell lung carcinoma, EGFR mutations, centers. The participants were requested to perform mutational anal- Quality assessment. ysis, using their usual method, and to submit results within a 4-week time frame. According to a predefined scoring system, two points (J Thorac Oncol. 2013;8: 773-778) were assigned to correct genotype and zero points to false-negative or false-positive results. The
Journal
Journal of Thoracic Oncology
– Wolters Kluwer Health
Published: Jun 1, 2013
Recommended Articles
Loading...
References
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Lynch
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
Paez
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao
Epidermal growth factor receptor mutations in lung cancer
Sharma
Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer
De Luca
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Linardou
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment
Marchetti
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
Mok
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)
Fukuoka
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
Maemondo
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou
Share the Full Text of this Article with up to 5 Colleagues for FREE
Sign up for your 14-Day Free Trial Now!
Read and print from thousands of top scholarly journals.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
